Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [5]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-15672 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- KLF4 Monoclonal Antibody (1E5)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MA5-15672 targets KLF4 in indirect ELISA, IHC and WB applications and shows reactivity with Human samples. The MA5-15672 immunogen is purified recombinant fragment of human KLF4 (Amino Acid: 2-470) expressed in E. Coli. MA5-15672 detects KLF4 which has a predicted molecular weight of approximately 55kDa.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 1E5
- Vial size
- 100 µL
- Concentration
- Conc. Not Determined
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Intratumoral Distribution of Lactate and the Monocarboxylate Transporters 1 and 4 in Human Glioblastoma Multiforme and Their Relationships to Tumor Progression-Associated Markers.
Genes Involved in the Transcriptional Regulation of Pluripotency Are Expressed in Malignant Tumors of the Uterine Cervix and Can Induce Tumorigenic Capacity in a Nontumorigenic Cell Line.
Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment.
Kubelt C, Peters S, Ahmeti H, Huhndorf M, Huber L, Cohrs G, Hövener JB, Jansen O, Synowitz M, Held-Feindt J
International journal of molecular sciences 2020 Aug 29;21(17)
International journal of molecular sciences 2020 Aug 29;21(17)
Genes Involved in the Transcriptional Regulation of Pluripotency Are Expressed in Malignant Tumors of the Uterine Cervix and Can Induce Tumorigenic Capacity in a Nontumorigenic Cell Line.
Ruiz G, Valencia-González HA, Pérez-Montiel D, Muñoz F, Ocadiz-Delgado R, Fernández-Retana J, Pérez-Plasencia C, Reséndis-Antonio O, Gariglio P, García-Carrancá A
Stem cells international 2019;2019:7683817
Stem cells international 2019;2019:7683817
Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment.
Adamski V, Hempelmann A, Flüh C, Lucius R, Synowitz M, Hattermann K, Held-Feindt J
Oncotarget 2017 Dec 8;8(64):108064-108078
Oncotarget 2017 Dec 8;8(64):108064-108078
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of KLF4 using KLF4 monoclonal antibody (Product # MA5-15672) in KLF4 (aa2-470) human IgG Fc transfected HEK293 (1) and HEK293 (2) cell lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of paraffin-embedded lung cancer tissues (left) and human rectum tissues (right) using KLF4 monoclonal antibody (Product # MA5-15672) followed with DAB staining.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 OSKM-N proteins are expressed in cervical cancer. (a) Expression levels of OCT4 (i), SOX2 (ii), KLF4 (iii), C-MYC (iv), and NANOG (v) proteins in cervical cancer tumors were measured by western blot (WB). Tumor samples (T1-T10) were compared with a nontumor sample (NT1). WB experiments were performed in triplicate; the values are expressed as mean +- standard deviation (normalized to beta -actin) using densitometric analysis. (b) The expression of OSKM-N in tumor cells from T1 and T2 samples was observed by immunohistochemistry (arrows). x20 magnification. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5 Representative co-staining of MCT1 with EMT markers (beta-catenin, vimentin), stem-like cell markers (KLF4, OCT4, Sox2), dormancy markers (EPHA5, H2BK, IGFBP5) and GFAP, as well as vWF in pairs of center and edge glioblastoma samples as determined by immunofluorescence microscopy. MCT1 and MCT4 (green) are found in different combinations with cell-specific markers (red) in a complex pattern. Magnification 400x; bar = 20 mum.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 Representative co-staining of MCT4 with EMT markers (beta-catenin, vimentin), stem-like cell markers (KLF4, OCT4, Sox2), dormancy markers (EPHA5, H2BK, IGFBP5) and GFAP, as well as vWF, in pairs of center and edge glioblastoma samples, as determined by immunofluorescence microscopy. MCT1 and MCT4 (green) are found in different combinations with cell-specific markers (red) in a complex pattern. Magnification 400x; bar = 20 mum.